Aiforia

Deep learning image analysis is the entire product. The Aiforia Clinical Suites are AI models plus a viewer, spanning breast, prostate, lung, colorectal, and gastric cancer plus lymph node metastasis detection, with no services or hardware layer. A separate Aiforia Create platform lets pathologists build their own models, which has produced a large body of third party research use models. The company sells the AI, not a workflow it happens to include.

Positioned throughout as pathologist support, not replacement. The clinical suites present findings for the pathologist to review and report, and the marketed benefit is time saved and consistency rather than autonomous sign out. Lymph node metastasis detection is framed as speeding navigation to relevant regions rather than making the call. This is an assistive tool with the human retaining the diagnosis, disclosed clearly and consistently.

Individual clinical models are described specifically, including the five model architecture behind breast cancer grading mapped to the Nottingham system components, and recent models are built on a foundation engine intended to hold up across variation in staining and scanning. Development partners are named by institution, University of Bern for lymph node metastasis for example. What is not published is training set size, demographic composition, or head to head benchmarking against competing pathology AI, so the transparency is descriptive rather than quantitative.

A real deployment record supports the claims: named clinical partners including AP-HP in Paris, Nantes University Hospital, Institut Curie, and a regional selection by the Lombardy health authorities in Italy for breast, lung, and prostate biopsy analysis. Academic work using the Aiforia Create platform appears in Nature and in Mayo Clinic and MSKCC studies, though most of that is research use rather than validation of the clinical suites. Vendor quoted efficiency figures such as up to 40 percent pathologist time saved on lymph node review are not independently verified here. Strong adoption signal, lighter published outcome evidence.

No specific PHI handling or data governance framework was located in the materials reviewed. The cloud based delivery and multi jurisdiction European deployment make data stewardship terms a per contract question.

No HIPAA or BAA commitment was located. The company is Helsinki headquartered with a US subsidiary, but its clinical products are marketed under European IVDR rather than to US clinical buyers, so a US health system would need to establish business associate terms directly.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in public materials. IVDR certification covers device safety and performance, not information security, so it does not substitute here.

The regulatory footprint is real but European, not American. Aiforia obtained IVDR certification through notified body BSI Group in February 2025 and has since launched a series of CE-IVD marked clinical models under IVDR 2017/746 covering breast, prostate, gastric, and lymph node applications. IVDR is a rigorous framework with stricter clinical evidence requirements than the directive it replaced. What is absent is any FDA clearance for the clinical suites, so a US buyer cannot deploy these diagnostically without a separate regulatory path. Graded C to reflect strong non US authorization with no US clinical clearance, the mirror image of vendors cleared by FDA but not CE marked.

No formal governance framework, subgroup performance analysis, or bias disclosure was located. IVDR post market surveillance obligations apply but the company does not publish its monitoring approach or demographic performance breakdowns.

Delivered as cloud based whole slide image analysis, which places it in the laboratory information system and image management environment rather than the EHR. A sales and marketing partnership with Siemens Healthineers extends distribution reach. Specific LIS, scanner, and image management system integrations are not enumerated in the materials reviewed, so integration depth is asserted through partnerships rather than a published connector list.

Cloud based delivery is the described model, with a French subsidiary established partly to support local presence for European customers. Specific hosting, tenancy, and data residency terms are not published, which matters for pathology given whole slide images are large and jurisdiction sensitive under IVDR and GDPR.

No product pricing is published. As a company publicly traded on the Helsinki exchange, Aiforia discloses revenue and financial performance under listing requirements, giving a buyer more visibility into vendor stability than most private pathology AI competitors, but nothing on per case, per model, or platform licensing cost.

Focused on anatomic pathology across a widening set of tumor types, breast, prostate, lung, colorectal, gastric, plus lymph node metastasis across three primary cancers, with a distinct preclinical and research business through Aiforia Create alongside the clinical suites. That dual footprint, clinical diagnostics and research model building, is a differentiator, though the clinical side is concentrated in oncology histopathology rather than spanning general pathology.